| DC Field | Value | Language |
|---|
| dc.contributor.author | Marwan Al-Nimer | - |
| dc.contributor.author | Vian Wasta Esmail | - |
| dc.contributor.author | Tavga Aziz | - |
| dc.date.accessioned | 2026-10-13T07:26:53Z | - |
| dc.date.available | 2026-10-13T07:26:53Z | - |
| dc.date.issued | 2026 | - |
| dc.identifier.citation | Marwan Al-Nimer. Reasons for using carnitine in managing dioxins-induced metabolic dysfunction-associated steatotic liver disease: A scoping review / Al-Nimer Marwan, Wasta Esmail Vian, Aziz Tavga // Research Results in Pharmacology. - 2026. - Vol.12, №2.-P. 20-34. - DOI: 10.18413/rrpharmacology.12.729. - Refer.: p. 29-34. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/67122 | - |
| dc.description.abstract | The mechanisms by which dioxin-induced MASLAD can be counteracted by L-carnitine or acetyl-L-carnitine at the same site of dioxin effects are discussed in this scoping review | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | acetyl-L-carnitine | ru |
| dc.subject | aryl hydrocarbon receptors | ru |
| dc.subject | carnitine | ru |
| dc.subject | dioxin | ru |
| dc.subject | metabolic dysfunction | ru |
| dc.subject | steatotic liver disease | ru |
| dc.title | Reasons for using carnitine in managing dioxins-induced metabolic dysfunction-associated steatotic liver disease: A scoping review | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 12, № 2
|
